FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1946113947> ?p ?o ?g. }

• W1946113947 endingPage "4119" @default.
• W1946113947 startingPage "4113" @default.
• W1946113947 abstract "The effect of 6-aminonicotinamide on the metabolism of RIF-1 tumor cells was investigated using 13C and 31P NMR spectroscopy. 6-Aminonicotinamide can be metabolized to 6-amino-NAD(P), a competitive inhibitor of NAD(P)-requiring processes. 40 μM 6-aminonicotinamide led to an inhibition of 6-phosphogluconate dehydrogenase and an accumulation of 6-phosphogluconate. A subsequent accumulation of the 6-phosphogluconate precursor 6-phosphoglucono-δ-lactone was observed in the 13C NMR spectrum. These metabolites were shown to be intracellular, although a small amount of leakage of 6-phosphoglucono-δ-lactone occurred. The intracellular concentrations of 6-phosphogluconate and 6-phosphoglucono-δ-lactone were 1.9 ± 0.8 μmol/108 cells (±1 standard deviation) and 0.8 ± 0.4 μmol/108 cells, respectively, after 15 h. Glucose utilization and lactate production were significantly inhibited by 6-aminonicotinamide (both p < 0.05), indicating inhibition of glycolysis. 31P NMR data showed that phosphocreatine was significantly depleted in cells exposed to 6-aminonicotinamide (p < 0.05). Exposure of RIF-1 cells to 6-aminonicotinamide prior to 3- or 6-Gy x-irradiation induced a supra-additive cell kill, indicating that 6-aminonicotinamide is acting as a radiosensitizer. There was no effect of 6-aminonicotinamide alone or when the drug was given postradiation, suggesting that its mechanism of action may be by inhibition of radiation-induced repair. The effect of 6-aminonicotinamide on the metabolism of RIF-1 tumor cells was investigated using 13C and 31P NMR spectroscopy. 6-Aminonicotinamide can be metabolized to 6-amino-NAD(P), a competitive inhibitor of NAD(P)-requiring processes. 40 μM 6-aminonicotinamide led to an inhibition of 6-phosphogluconate dehydrogenase and an accumulation of 6-phosphogluconate. A subsequent accumulation of the 6-phosphogluconate precursor 6-phosphoglucono-δ-lactone was observed in the 13C NMR spectrum. These metabolites were shown to be intracellular, although a small amount of leakage of 6-phosphoglucono-δ-lactone occurred. The intracellular concentrations of 6-phosphogluconate and 6-phosphoglucono-δ-lactone were 1.9 ± 0.8 μmol/108 cells (±1 standard deviation) and 0.8 ± 0.4 μmol/108 cells, respectively, after 15 h. Glucose utilization and lactate production were significantly inhibited by 6-aminonicotinamide (both p < 0.05), indicating inhibition of glycolysis. 31P NMR data showed that phosphocreatine was significantly depleted in cells exposed to 6-aminonicotinamide (p < 0.05). Exposure of RIF-1 cells to 6-aminonicotinamide prior to 3- or 6-Gy x-irradiation induced a supra-additive cell kill, indicating that 6-aminonicotinamide is acting as a radiosensitizer. There was no effect of 6-aminonicotinamide alone or when the drug was given postradiation, suggesting that its mechanism of action may be by inhibition of radiation-induced repair." @default.
• W1946113947 created "2016-06-24" @default.
• W1946113947 creator A5002640981 @default.
• W1946113947 creator A5036062833 @default.
• W1946113947 creator A5063494562 @default.
• W1946113947 creator A5065214430 @default.
• W1946113947 creator A5069791774 @default.
• W1946113947 date "1996-02-01" @default.
• W1946113947 modified "2023-10-17" @default.
• W1946113947 title "13C and 31P NMR Investigation of Effect of 6-Aminonicotinamide on Metabolism of RIF-1 Tumor Cells in Vitro" @default.
• W1946113947 cites W109810485 @default.
• W1946113947 cites W127072620 @default.
• W1946113947 cites W1486843536 @default.
• W1946113947 cites W1536351550 @default.
• W1946113947 cites W1640012713 @default.
• W1946113947 cites W1965446112 @default.
• W1946113947 cites W1979992202 @default.
• W1946113947 cites W1980451556 @default.
• W1946113947 cites W1981156748 @default.
• W1946113947 cites W1984660815 @default.
• W1946113947 cites W1988433987 @default.
• W1946113947 cites W1993823258 @default.
• W1946113947 cites W1998264209 @default.
• W1946113947 cites W2001186301 @default.
• W1946113947 cites W2001759812 @default.
• W1946113947 cites W2009510636 @default.
• W1946113947 cites W2011250388 @default.
• W1946113947 cites W2011947350 @default.
• W1946113947 cites W2027000049 @default.
• W1946113947 cites W2037497911 @default.
• W1946113947 cites W2054111304 @default.
• W1946113947 cites W2081849752 @default.
• W1946113947 cites W2082285056 @default.
• W1946113947 cites W2083808983 @default.
• W1946113947 cites W2084247271 @default.
• W1946113947 cites W2085446645 @default.
• W1946113947 cites W2156296351 @default.
• W1946113947 cites W2168964499 @default.
• W1946113947 cites W2336356469 @default.
• W1946113947 cites W2413971748 @default.
• W1946113947 cites W4241281124 @default.
• W1946113947 cites W4864661 @default.
• W1946113947 doi "https://doi.org/10.1074/jbc.271.8.4113" @default.
• W1946113947 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8626749" @default.
• W1946113947 hasPublicationYear "1996" @default.
• W1946113947 type Work @default.
• W1946113947 sameAs 1946113947 @default.
• W1946113947 citedByCount "34" @default.
• W1946113947 countsByYear W19461139472012 @default.
• W1946113947 countsByYear W19461139472013 @default.
• W1946113947 countsByYear W19461139472017 @default.
• W1946113947 countsByYear W19461139472018 @default.
• W1946113947 countsByYear W19461139472019 @default.
• W1946113947 countsByYear W19461139472020 @default.
• W1946113947 countsByYear W19461139472021 @default.
• W1946113947 countsByYear W19461139472022 @default.
• W1946113947 crossrefType "journal-article" @default.
• W1946113947 hasAuthorship W1946113947A5002640981 @default.
• W1946113947 hasAuthorship W1946113947A5036062833 @default.
• W1946113947 hasAuthorship W1946113947A5063494562 @default.
• W1946113947 hasAuthorship W1946113947A5065214430 @default.
• W1946113947 hasAuthorship W1946113947A5069791774 @default.
• W1946113947 hasBestOaLocation W19461139471 @default.
• W1946113947 hasConcept C109316439 @default.
• W1946113947 hasConcept C126322002 @default.
• W1946113947 hasConcept C181199279 @default.
• W1946113947 hasConcept C185592680 @default.
• W1946113947 hasConcept C20251656 @default.
• W1946113947 hasConcept C202751555 @default.
• W1946113947 hasConcept C2776428644 @default.
• W1946113947 hasConcept C2779728014 @default.
• W1946113947 hasConcept C2780017796 @default.
• W1946113947 hasConcept C509974204 @default.
• W1946113947 hasConcept C55493867 @default.
• W1946113947 hasConcept C62231903 @default.
• W1946113947 hasConcept C66974803 @default.
• W1946113947 hasConcept C71240020 @default.
• W1946113947 hasConcept C71924100 @default.
• W1946113947 hasConcept C75520062 @default.
• W1946113947 hasConcept C79879829 @default.
• W1946113947 hasConceptScore W1946113947C109316439 @default.
• W1946113947 hasConceptScore W1946113947C126322002 @default.
• W1946113947 hasConceptScore W1946113947C181199279 @default.
• W1946113947 hasConceptScore W1946113947C185592680 @default.
• W1946113947 hasConceptScore W1946113947C20251656 @default.
• W1946113947 hasConceptScore W1946113947C202751555 @default.
• W1946113947 hasConceptScore W1946113947C2776428644 @default.
• W1946113947 hasConceptScore W1946113947C2779728014 @default.
• W1946113947 hasConceptScore W1946113947C2780017796 @default.
• W1946113947 hasConceptScore W1946113947C509974204 @default.
• W1946113947 hasConceptScore W1946113947C55493867 @default.
• W1946113947 hasConceptScore W1946113947C62231903 @default.
• W1946113947 hasConceptScore W1946113947C66974803 @default.
• W1946113947 hasConceptScore W1946113947C71240020 @default.
• W1946113947 hasConceptScore W1946113947C71924100 @default.
• W1946113947 hasConceptScore W1946113947C75520062 @default.
• W1946113947 hasConceptScore W1946113947C79879829 @default.
• W1946113947 hasIssue "8" @default.

• next